Verseon Corporation Result of AGM and changes to the Board (4533G)
2018年11月6日 - 4:00PM
RNSを含む英国規制内ニュース (英語)
TIDMVSN
RNS Number : 4533G
Verseon Corporation
06 November 2018
November 6, 2018
Verseon Corporation
("Verseon" or the "Company")
Result of AGM and changes to the Board
Fremont, Calif.-Verseon Corporation (AIM:VSN), a
technology-based pharmaceutical company, announces that all
resolutions put to shareholders were duly passed during the Annual
General Meeting ("AGM") held on November 5, 2018 at 14:00 PDT.
During the AGM, the Company also announced to shareholders that
Xavier Rolet and Sangtae Kim are joining the Board as non-executive
directors of Verseon, subject to the completion of normal and
customary regulatory diligence.
The Company reports that Robert Karr and Grover Wickersham have
stepped down from the Board. "We want to thank Robert and Grover
for their valuable service and contributions in overseeing the
growth of Verseon," said Thomas Hecht, Chairman of the Board of
Directors.
Xavier Rolet has broad leadership experience in the global
financial community. Most recently, he was the CEO of the London
Stock Exchange Group (LSEG) from May 2009 to December 2017, during
which time the market capitalization of LSEG rose from GBP800
million to GBP14 billion. Prior to LSEG, Xavier held leadership
roles in New York, London, and Paris offices for Lehman Brothers,
and held senior positions at global investment banks Kleinwort
Benson, Credit Suisse and Goldman Sachs. Xavier was a member of the
Business Advisory Group of former British Prime Minister David
Cameron, the Financial Services Forum of the Governor of the Bank
of England, and the Bank of England's Open Forum. He holds the
ranks of Honorary Knight Commander of the Most Excellent Order of
the British Empire (KBE).
Sangtae Kim has a distinguished career in chemical engineering
with senior roles in both industry and academia. He is a former VP
of Lilly Research Laboratories, a division of Eli Lilly, and a
former VP at Parke-Davis Pharmaceutical Research. Sangtae is the
founding Director of the National Science Foundation Division of
Shared Cyberinfrastructure and a former Executive Director of the
Morgridge Institute for Research. He is a Distinguished Professor
of Chemical Engineering at Purdue University and a former faculty
member at the University of Wisconsin-Madison. Sangtae is a member
of the National Academy of Engineering and a Trustee of the AlChE
(American Institute of Chemical Engineers) Foundation. His honors
and awards include the 2013 Ho-Am Prize in Engineering, AICHE's
George Lappin Award (2008) and Colburn Award (1993), and the 1992
Award for Initiatives in Research from the National Academy of
Sciences.
"We look forward to working with Xavier and Sangtae," commented
Adityo Prakash, Verseon CEO. "Sangtae is a pioneer in the
pharmaceutical industry, and his vision will be an invaluable as we
grow our drug development pipeline. Xavier's extensive experience
in the global finance industry will greatly benefit our board and
our management team as we introduce our novel blockchain technology
for tokenized securities to the financial world."
About Verseon
Verseon Corporation (www.verseon.com, AIM: VSN) is developing
disruptive life-science technology to advance global health. The
clinical-phase Company is using its proprietary, computational drug
discovery platform paired with a comprehensive in-house chemistry
and biology workflow to build a growing drug development pipeline.
Through its wholly owned subsidiary BlockRules Ltd., Verseon is
also pioneering blockchain technology for regulated securities.
-Ends-
For further information, please contact
Verseon Corporation www.verseon.com
Sebastian Wykeham +1 (510) 225 9000
Arden Partners (NOMAD and Joint Broker)
Ruari McGirr / Ciaran Walsh / Maria +44 (0) 20 7614
Gomez De Olea 5900
Cantor Fitzgerald Europe (Joint Broker)
+44 (0) 20 7894
Marc Milmo / Phil Davies 7000
For financial and business media enquiries, please contact
Buchanan Communications Ltd (PR Advisers)
+44 (0) 20 7466
Henry Harrison-Topham / Jamie Hooper 5000
For trade and pharma media enquiries, please contact
Vane Percy & Roberts
+44 (0) 1737 821
Simon Vane Percy 890
Forward-Looking Statements
This press release contains forward-looking statements, which
are generally statements that are not historical facts.
Forward-looking statements can be identified by the words
"expects," "anticipates," "believes," "intends, " "estimates,"
"plans," "will," "outlook," and similar expressions.
Forward-looking statements are based on management's current plans,
estimates, assumptions, and projections, and speak only as of the
date they are made. We undertake no obligation to update any
forward-looking statement in light of new information or future
events, except as otherwise required by law. Forward-looking
statements involve inherent risks and uncertainties, most of which
are difficult to predict and are generally beyond our control.
Actual results or outcomes may differ materially from those implied
by the forward-looking statements as a result of the impact of a
number of factors.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCZMMGMVVVGRZG
(END) Dow Jones Newswires
November 06, 2018 02:00 ET (07:00 GMT)
Verseon (LSE:VSN)
過去 株価チャート
から 5 2024 まで 6 2024
Verseon (LSE:VSN)
過去 株価チャート
から 6 2023 まで 6 2024